|
|
| Oncologie > Etude de marché sectorielle |
| Ovarian Cancer Therapeutics |
|
|
|
|
€ 3 012,00 |
Editeur
: |
Global Industry Analyst |
Langue
: |
Anglais |
Date de publication : |
Février 2006 |
Taille du document : |
248 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
MarketWatch: Cancer
33 pages | Mars 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
MarketWatch: Cancer
32 pages | Juillet 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
Cancer Vaccines: Measuring Market Potential
232 pages | Octobre 2004 |
This report provides an overview of the emerging market for cancer vaccines and measures their potential impact on a number of cancer markets.
Vaccine product candidates are discussed within the co |
1 200,00 €
|
| |
| |
MarketWatch: Cancer
29 pages | Octobre 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
170,00 €
|
| |
| |
Market Leaders in Oncology 2004 - Roche and Genentech Continue to Blaze a Trail
71 pages | Janvier 2005 |
IntroductionRoche continues to lead the oncology sector, recording oncology sales of $5,719m in 2003.
This sector dominance is predicted to continue between 2004 and 2010, due to Roche's ability to |
3 040,00 €
|
| |
| |
Pipeline Insight: Cancer Vaccines and Cell Therapies - Technical Know How Needs Translation Into Clinical and Commercial Rewards
203 pages | Avril 2005 |
IntroductionUnmet need across the cancer market is high, with most therapies conferring low levels of specificity and high toxicity.
Development of cancer vaccines may be the holy grail, with the p |
9 120,00 €
|
| |
| |
Commercial Insight Top 20 Cancer Therapeutics
197 pages | Juillet 2006 |
IntroductionThe Top 20 cancer therapeutics generated sales of $20.1 billion in 2005 across the seven markets, set to reach $27.4 billion by 2015.
Cytotoxics currently constitute the majority, due t |
12 160,00 €
|
| |
| |
The Cancer Outlook 2000
128 pages | Septembre 2000 |
Driven by the cytotoxic, adjunct and innovative drug classes, the cancer market grew by 16% in 1999 to a global value of almost $19bn, and is now poised on the verge of a period of significant exp |
955,00 €
|
| |
| |
MarketWatch: Cancer
27 pages | Mai 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
MarketWatch: Cancer
29 pages | Décembre 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
170,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Ovarian Cancer Therapeutics |
|
|
This report analyzes the worldwide markets for Ovarian Cancer Therapeutics in Millions of US$. The major product segments analyzed are Localized Ovarian Cancer Therapeutics, Metastatic Ovarian Cancer Therapeutics, and Refractory Ovarian Cancer Therapeutics. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2010. The report profiles 42 companies including many key and niche players worldwide such as Alza Corporation, Amgen, Inc., Bristol-Myers Squibb, Cell Therapeutics, Inc., Genentech Inc., GlaxoSmithkline, Immunogen, Inc., Ivax, OSI Pharmaceuticals, and Raven Biotechnologies, Inc.
|
|
Ovarian Cancer Therapeutics
|
|
|
PPLSEN
|
|
|
|
|
